Cargando…

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials

Neoadjuvant chemoradiotherapy (NCRT) plus radical esophagectomy is currently the standard treatment for resectable esophageal or gastroesophageal junction (GEJ) carcinoma. The aim of this study is to evaluate the efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or GEJ carcin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jie, Leng, Xuefeng, Gao, Binyang, Wang, Bo, Zhang, Hanlin, Wu, Lei, Ma, Jiabao, Tan, Yan, Peng, Lin, Han, Yongtao, Wang, Qifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800859/ https://www.ncbi.nlm.nih.gov/pubmed/36591306 http://dx.doi.org/10.3389/fimmu.2022.1041233

Ejemplares similares

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
por: He, Wenwu, et al.
Publicado: (2022)

Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer
por: Ahmad, M. Usman, et al.
Publicado: (2022)

Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis
por: Xu, Jiawei, et al.
Publicado: (2022)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis
por: Wang, Hesong, et al.
Publicado: (2023)

Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
por: Jiang, Li, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
por: Liu, Yunsong, et al.
Publicado: (2023)

Correction to: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
por: Jiang, Li, et al.
Publicado: (2023)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
por: Faron, Matthieu, et al.
Publicado: (2023)

Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis
por: Qin, Hao, et al.
Publicado: (2023)

Techniques and short-term outcomes for total minimally invasive Ivor Lewis esophageal resection in distal esophageal and gastroesophageal junction cancers: pooled data from six European centers
por: Straatman, Jennifer, et al.
Publicado: (2016)

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
por: Li, Shoumiao, et al.
Publicado: (2017)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
por: Duan, Hongtao, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

Comparison  of  efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma
por: Lyu, Jiahua, et al.
Publicado: (2019)

Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas
por: Ferrer-Torres, Daysha, et al.
Publicado: (2016)

Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis
por: Yu, Guocan, et al.
Publicado: (2021)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022)

Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Biomarkers for immunotherapy in esophageal cancer
por: Wang, Xuelian, et al.
Publicado: (2023)

Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis
por: Xu, Hao, et al.
Publicado: (2023)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors
por: McGillivray, Erin, et al.
Publicado: (2023)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy
por: Wang, Qifeng, et al.
Publicado: (2014)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials
por: Zhao, Xin, et al.
Publicado: (2018)

Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review
por: Li, Xiaoying, et al.
Publicado: (2021)

EUS–derived maximum tumor thickness and tumor shrinkage rate as independent prognostic factors in locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
por: Chen, Xue, et al.
Publicado: (2023)

Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers
por: Kastelowitz, Noah, et al.
Publicado: (2021)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kl8no3p9psgqev4iopmqogpsbt